Rhumbline Advisers Olema Pharmaceuticals, Inc. Put Options Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding OLMA
# of Institutions
126Shares Held
67.8MCall Options Held
0Put Options Held
31.4K-
Bain Capital Life Sciences Investors, LLC Boston, MA6.84MShares$36.3 Million8.75% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.76MShares$35.9 Million1.35% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$28.1 Million0.89% of portfolio
-
Black Rock Inc. New York, NY4MShares$21.2 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.51MShares$18.6 Million0.08% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $215M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...